CombiMatrix Molecular Diagnostics

CombiMatrix was a clinical diagnostic laboratory specializing in molecular testing for prenatal, postnatal, and oncology applications. The company was a pioneer in the use of chromosomal microarray analysis (CMA) to identify genetic abnormalities associated with miscarriages, developmental delays, and hematological malignancies. Their services provided higher resolution and faster results compared to traditional karyotyping, aiding clinicians in complex genetic diagnosis. CombiMatrix was acquired by Invitae in 2017, integrating its specialized reproductive and oncology testing into Invitae's broader genetic testing platform.